Monte Rosa Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Monte Rosa Therapeutics, Inc. (GLUE) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $473.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was $473.00K.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$974.00K.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $93.00K.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $73.00K, a 76.53% decline year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was $48.00K, a 71.76% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was $170.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $473.00K 10-Q · filed 2026-08-06 | -$501.00K derived: sum of 2 quarters · filed 2026-08-06 | -$408.00K derived: sum of 3 quarters · filed 2026-08-06 | -$335.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$974.00K 10-Q · filed 2026-08-06 | -$881.00K derived: sum of 2 quarters · filed 2026-08-06 | -$808.00K derived: sum of 3 quarters · filed 2026-08-06 | -$905.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $166.00K derived: sum of 2 quarters · filed 2026-03-17 | $69.00K derived: sum of 3 quarters · filed 2026-08-06 | $48.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $73.00K 10-Q · filed 2025-11-06 | -$24.00K derived: sum of 2 quarters · filed 2026-08-06 | -$45.00K 10-Q · filed 2025-11-06 | -$170.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$97.00K 10-Q · filed 2026-08-06 | -$118.00K derived: sum of 2 quarters · filed 2026-08-06 | -$243.00K derived: sum of 3 quarters · filed 2026-08-06 | $68.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$21.00K 10-Q · filed 2026-08-06 | -$146.00K derived: sum of 2 quarters · filed 2026-08-06 | $165.00K derived: sum of 3 quarters · filed 2026-08-06 | $153.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $186.00K derived: sum of 2 quarters · filed 2026-03-17 | $174.00K derived: sum of 3 quarters · filed 2026-03-17 | $170.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $311.00K 10-Q · filed 2025-11-06 | $299.00K derived: sum of 2 quarters · filed 2025-11-06 | $295.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$12.00K 10-Q · filed 2025-11-06 | -$16.00K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | -$4.00K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |